President & CEO Raab Michael exercised 25,000 shares at a strike of $0.99 and sold $131,620 worth of shares (25,000 units at $5.26) (SEC Form 4)

$ARDX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ARDX alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
RAAB MICHAEL

(Last) (First) (Middle)
C/O ARDELYX, INC.
400 FIFTH AVENUE, SUITE 210

(Street)
WALTHAM MA 02451

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ARDELYX, INC. [ ARDX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President & CEO
3. Date of Earliest Transaction (Month/Day/Year)
12/10/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/10/2024 M(1) 25,000 A $0.99 1,175,385 D
Common Stock 12/10/2024 S(1) 25,000 D $5.2648(2) 1,150,385 D
Common Stock 24,364 I Family Trust(3)
Common Stock 1,000 I Family Trust(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $0.99 12/10/2024 M 25,000 (5) 01/06/2032 Common Stock 25,000 $0 520,000 D
Explanation of Responses:
1. Transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 13, 2023.
2. Transaction was executed in multiple trades in prices ranging from $5.22 to $5.33, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. The shares are directly held by Michael G. Raab, Trustee of the Michael G. Raab Living Trust dated July 25, 2012.
4. The shares are owned directly by trusts for the benefit of the Reporting Person's children.
5. The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Remarks:
/s/ Elizabeth Grammer, Attorney-in-Fact for Michael Raab 12/12/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $ARDX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ARDX

DatePrice TargetRatingAnalyst
11/11/2024$11.00 → $5.50Buy → Neutral
H.C. Wainwright
7/2/2024$15.00 → $7.00Overweight → Neutral
Piper Sandler
4/5/2024$14.00Outperform
Leerink Partners
12/18/2023$12.00Strong Buy
Raymond James
9/7/2023$9.00Buy
H.C. Wainwright
8/25/2023$5.00 → $10.00Neutral → Overweight
Cantor Fitzgerald
3/3/2023$3.00 → $6.00Neutral → Outperform
Wedbush
11/17/2022$3.00 → $8.00Neutral → Overweight
Piper Sandler
More analyst ratings

$ARDX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    Company achieved significant commercial progress in 2024, finishing with total revenue of $333.6 million, including $319.2 million in U.S. Net Product Sales Company reaffirms combined peak sales of IBSRELA and XPHOZAH of $1.75 Billion Company ended FY 2024 with $250.1 million in cash, cash equivalents and investments Conference call scheduled for 8:00 AM Eastern Time WALTHAM, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year ended

    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference

    WALTHAM, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that management will present at TD Cowen's 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:50am ET in Boston. To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the panel presentation will be available on the Ardelyx website for 30 days following the event. About Ardelyx, I

    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025

    WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 20, 2025, at 8:00 a.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2024. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be avail

    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ARDX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ARDX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ARDX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ARDX
SEC Filings

See more

$ARDX
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FDA Approval for XPHOZA™ issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZA™ (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ARDX
Leadership Updates

Live Leadership Updates

See more
  • Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer

    WALTHAM, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Eric Foster as the company's Chief Commercial Officer. Mr. Foster is an experienced leader with more than 23 years of commercial experience for significant global biotech and pharmaceutical companies across numerous complex rare disease and specialty markets. Mr. Foster will be responsible for leading all commercial strategies for the company's two first-in-class medicines, IBSRELA® (tenapanor) and XPHOZAH® (te

    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy

    WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Mike Kelliher to the position of Executive Vice President, Corporate Development and Strategy. Mr. Kelliher, an accomplished leader with more than 20 years of experience in the biopharmaceutical industry, brings to Ardelyx an extensive array of mergers and acquisitions, business development, strategy, finance and operational leadership expertise from leading biotechnology and global pharmaceutical companies.

    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors

    CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced the appointment of Muna Bhanji, R.Ph., to its board of directors. "We welcome Muna whose deep expertise in global commercialization and market access will be critical to Intellia as we expand our leadership position in the field of genome editing and move closer to commercializing potentially curative treatments for people with life-threatening diseases," said Intellia President and Chief Executive Officer John Leonard, M.D. "We are very fortunate to benef

    $ARDX
    $CYTK
    $NTLA
    $VCYT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Medical Specialities

$ARDX
Financials

Live finance-specific insights

See more
  • Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    Company achieved significant commercial progress in 2024, finishing with total revenue of $333.6 million, including $319.2 million in U.S. Net Product Sales Company reaffirms combined peak sales of IBSRELA and XPHOZAH of $1.75 Billion Company ended FY 2024 with $250.1 million in cash, cash equivalents and investments Conference call scheduled for 8:00 AM Eastern Time WALTHAM, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year ended

    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025

    WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 20, 2025, at 8:00 a.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2024. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be avail

    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update

    IBSRELA generates $40.6 million in net product sales revenue; Company expects full year 2024 IBSRELA net sales revenue to be between $145 and $150 million XPHOZAH generates $51.5 million in net product sales revenue Company ends Q3 with approximately $190 million in cash, cash equivalents and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2024 and prov

    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ARDX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more